The companion FAQ sets out the evidence grades and the safety pillars so you can explore the picture with your team
The companies that are correctly positioned in this environment are those with robust pipeline depth, manufacturing efficiency advantages, and therapeutic areas where generic competition dynamics are unfavorable to Cost Plus-style pricing primarily biologics, where the regulatory and manufacturing complexity of biosimilar development creates slower and less complete price erosion than small-molecule generics experience
The multiple sclerosis (MS) genetic risk factors indicate both acquired and innate immune cell subsets contribute to ms pathogenesis and identify novel therapeutic oppor-tunities
Eli Lilly, the maker of Mounjaro and Zepbound, said Thursday that the company's new orforglipron pill can offer up to an average of 27.3 pounds of weight loss, according to results from the first of two of its Phase 3 trials that included more than 3,100 overweight or obese adults
A blood-based epigenetic clock for intrinsic capacity predicts mortality and is associated with clinical, immunological and lifestyle factors
